Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Directorate Change

Leeds, 26 February 2021 - Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that the Board has appointed Jonathan Glenn, current Interim Non-Executive Chairman, to the position of Non-Executive Chairman with immediate effect.

Jonathan joined the Group in January 2016, and was appointed Interim Non-Executive Chairman in March 2020.

Daniel Lee, Chief Executive Officer, of Tissue Regenix Group plc said: "We are delighted to have Jonathan appointed as Non-Executive Chairman to the Group. Jonathan's leadership has been invaluable over the last year, as Interim Chairman, and we look forward to his continued contribution towards the Company's future growth."

For more Information:

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.